Oct 16, 2026 06:23AM
Oct 16, 2026 02:51AM
Oct 15, 2026 09:46AM
Oct 15, 2026 09:45AM
Oct 5, 2026 08:01AM
Oct 5, 2026 08:00AM
Sep 14, 2026 04:06PM FDA grants breakthrough therapy status to Revolution Medicines drug for pancreatic cancer
Sep 14, 2026 04:05PM
Sep 10, 2026 03:39AM
Aug 28, 2026 08:12AM
Aug 27, 2026 07:00AM
Aug 26, 2026 05:01PM
Aug 26, 2026 02:04PM
Aug 26, 2026 12:59PM FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer
Aug 26, 2026 12:59PM
Aug 26, 2026 10:43AM
Aug 12, 2026 08:32AM
Aug 6, 2026 07:42AM
Aug 5, 2026 04:02PM
Jul 22, 2026 04:05PM
Jul 22, 2026 04:05PM Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
Jul 7, 2026 09:24AM
Jul 7, 2026 09:23AM
Jul 2, 2026 08:01AM
Jul 2, 2026 08:00AM
Jun 3, 2026 08:30AM
May 31, 2026 08:06AM
May 31, 2026 08:06AM Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic
May 21, 2026 04:38PM
May 6, 2026 06:00PM
May 6, 2026 06:00PM
May 6, 2026 04:02PM
May 1, 2026 12:54PM
Apr 21, 2026 11:23AM
Apr 21, 2026 11:23AM Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual
Apr 14, 2026 06:46AM
Apr 13, 2026 10:37AM
Apr 13, 2026 08:02AM
Apr 13, 2026 08:00AM
Feb 25, 2026 04:02PM
Jan 8, 2026 08:03AM
Jan 8, 2026 08:00AM Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
Dec 21, 2025 08:00PM
Nov 5, 2025 04:02PM
Oct 27, 2025 08:01AM
Oct 27, 2025 08:00AM
Oct 17, 2025 05:16AM
Oct 16, 2025 08:00PM
Aug 6, 2025 04:02PM Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
Jul 23, 2025 08:00AM

334,268 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All